ATRC (AtriCure) ROCE %: 1.21% (As of Mar. 2026)

What is AtriCure ROCE %?

AtriCure ATRC -0.11% 76 ROCE % is 1.21% as of Mar. 2026. GuruFocus rates ATRC with a GF Score™ of 76/100 and a GF Value™ of $39.73 (Modestly Undervalued). The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. AtriCure's annualized ROCE % for the quarter that ended in Mar. 2026 was 1.21%.

AtriCure (NAS:ATRC) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

AtriCure ROCE % Related Terms

AtriCure ROCE % Historical Data

* Premium members only.

The historical data trend for AtriCure's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AtriCure ROCE % Chart

AtriCure Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

9.03

-7.59

-4.30

-6.93

-0.77

AtriCure Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															-3.82	-3.32	1.01	2.73	1.21

76GF Score

AtriCure Inc ATRC

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

AtriCure ROCE % Calculation

AtriCure's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	-4.285	/	( ( (609.328 - 73.424)	+	(654.179 - 81.52) )	/ 2 )
	=	-4.285	/	( (535.904	+	572.659)	/ 2 )
	=	-4.285	/	554.2815
	=	-0.77 %

AtriCure's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	6.936	/	( ( (654.179 - 81.52)	+	(643.988 - 73.191) )	/ 2 )
	=	6.936	/	( ( 572.659	+	570.797 )	/ 2 )
	=	6.936	/	571.728
	=	1.21 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of 1.21% mean?

AtriCure (ATRC) has a ROCE % of 1.21% as of Mar. 2026.

Is AtriCure's ROCE % too high?

AtriCure's current ROCE % is 1.21%. The Medical Devices & Instruments industry median ROCE % is 2.23. AtriCure's value of 1.21% is 45.7% below this industry median. Overall, AtriCure has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does AtriCure's ROCE % compare to STAA and NNNN?

AtriCure's ROCE % of 1.21% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. AtriCure's value of 1.21% is 45.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Medical Devices & Instruments company?

The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AtriCure's current ROCE % of 1.21% is 45.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AtriCure's current ROCE % is 1.21%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is AtriCure stock overvalued right now?

Based on GuruFocus' analysis, AtriCure (ATRC) is currently considered Modestly Undervalued. The stock's GF Value™ is $39.73, compared to a current price of $28.41 — trading 28.5% below its estimated fair value. The current ROCE % is 1.21% and 45.7% below the Medical Devices & Instruments industry median of 2.23. AtriCure's overall GF Score™ is 76/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For AtriCure (ATRC), the current ROCE % is 1.21% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AtriCure (ATRC) Overvalued in 2026?

Based on GuruFocus' analysis, AtriCure stock appears to be undervalued. The current stock price of $28.41 is trading 28.5% below its estimated GF Value™ of $39.73. GuruFocus considers AtriCure to be Modestly Undervalued.

Key valuation signals for ATRC:

ROCE %: 1.21%
GF Value™: $39.73 vs. price of $28.41 (28.5% below fair value)
GF Score™: 76/100 with 1 warning sign
Industry Position: 45.7% below the Medical Devices & Instruments median

No single metric tells the full story. See the ATRC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AtriCure Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies STAA NNNN KMTS BLFS PLSE AZTA XRAY LMAT ANGO OSUR ISRG XPAR:EL TSE:7741 BDX XSWX:ALC MDLN RMD WST TSE:4543 XPAR:DIM

Address 7555 Innovation Way, Mason, OH, USA, 45040

Website https://www.atricure.com

AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.

76GF Score

Get the complete analysis for ATRC

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$28.41

Price

$39.73

GF Value

View ATRC Analysis

See ROCE % data for all stocks →